A Phase 1 Randomized, Placebo-Controlled Study to Determine the Effect of LY3316531 on Capsaicin-Induced Dermal Blood Flow in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs LY-3316531 (Primary)
- Indications Psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 10 Dec 2018 Planned End Date changed from 1 Jan 2019 to 18 Jan 2019.
- 10 Dec 2018 Planned primary completion date changed from 1 Jan 2019 to 18 Jan 2019.
- 10 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.